Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC
Phase of Trial: Phase IV
Latest Information Update: 18 Mar 2016
At a glance
- Drugs Maraviroc (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MARAVI-PEP
- 18 Mar 2016 Results published in the Journal of Antimicrobial Chemotherapy
- 14 Mar 2012 Status changed from recruiting to completed, according to European Clinical Trials Database.
- 14 Feb 2012 Additional lead trial center and investigator identiifed as reported by ClinicalTrials.gov.